Volume 118, Issue 4, Pages 661-669 (April 2000) Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa Elly C. Klinkenberg-Knol, Frits Nelis, John Dent, Pleun Snel, Brent Mitchell, Peter Prichard, David Lloyd, Niilo Havu, Madeline H. Frame, Jonas Romàn, Anders Walan Gastroenterology Volume 118, Issue 4, Pages 661-669 (April 2000) DOI: 10.1016/S0016-5085(00)70135-1 Copyright © 2000 American Gastroenterological Association Terms and Conditions
Fig. 1 Number of patients (▩) and number of relapses (■) during each year of the study. Gastroenterology 2000 118, 661-669DOI: (10.1016/S0016-5085(00)70135-1) Copyright © 2000 American Gastroenterological Association Terms and Conditions
Fig. 2 Proportion of H. pylori–positive (top panels) and H. pylori–negative (lower panels) patients with (A) inflammation, (B) activity, and (C) atrophy of the corpus mucosa at first and last visit. □, None; ▩, mild; ●, moderate; ■, severe. Gastroenterology 2000 118, 661-669DOI: (10.1016/S0016-5085(00)70135-1) Copyright © 2000 American Gastroenterological Association Terms and Conditions
Fig. 2 Proportion of H. pylori–positive (top panels) and H. pylori–negative (lower panels) patients with (A) inflammation, (B) activity, and (C) atrophy of the corpus mucosa at first and last visit. □, None; ▩, mild; ●, moderate; ■, severe. Gastroenterology 2000 118, 661-669DOI: (10.1016/S0016-5085(00)70135-1) Copyright © 2000 American Gastroenterological Association Terms and Conditions
Fig. 2 Proportion of H. pylori–positive (top panels) and H. pylori–negative (lower panels) patients with (A) inflammation, (B) activity, and (C) atrophy of the corpus mucosa at first and last visit. □, None; ▩, mild; ●, moderate; ■, severe. Gastroenterology 2000 118, 661-669DOI: (10.1016/S0016-5085(00)70135-1) Copyright © 2000 American Gastroenterological Association Terms and Conditions
Fig. 2 Proportion of H. pylori–positive (top panels) and H. pylori–negative (lower panels) patients with (A) inflammation, (B) activity, and (C) atrophy of the corpus mucosa at first and last visit. □, None; ▩, mild; ●, moderate; ■, severe. Gastroenterology 2000 118, 661-669DOI: (10.1016/S0016-5085(00)70135-1) Copyright © 2000 American Gastroenterological Association Terms and Conditions
Fig. 2 Proportion of H. pylori–positive (top panels) and H. pylori–negative (lower panels) patients with (A) inflammation, (B) activity, and (C) atrophy of the corpus mucosa at first and last visit. □, None; ▩, mild; ●, moderate; ■, severe. Gastroenterology 2000 118, 661-669DOI: (10.1016/S0016-5085(00)70135-1) Copyright © 2000 American Gastroenterological Association Terms and Conditions
Fig. 2 Proportion of H. pylori–positive (top panels) and H. pylori–negative (lower panels) patients with (A) inflammation, (B) activity, and (C) atrophy of the corpus mucosa at first and last visit. □, None; ▩, mild; ●, moderate; ■, severe. Gastroenterology 2000 118, 661-669DOI: (10.1016/S0016-5085(00)70135-1) Copyright © 2000 American Gastroenterological Association Terms and Conditions
Fig. 3 Proportion of (A) H. pylori–positive and (B) H. pylori–negative patients with diffuse (▩), linear (●), micronodular (■), and no (□) argyrophil cell hyperplasia at first and last visit. Gastroenterology 2000 118, 661-669DOI: (10.1016/S0016-5085(00)70135-1) Copyright © 2000 American Gastroenterological Association Terms and Conditions
Fig. 3 Proportion of (A) H. pylori–positive and (B) H. pylori–negative patients with diffuse (▩), linear (●), micronodular (■), and no (□) argyrophil cell hyperplasia at first and last visit. Gastroenterology 2000 118, 661-669DOI: (10.1016/S0016-5085(00)70135-1) Copyright © 2000 American Gastroenterological Association Terms and Conditions